08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

BSD Medical management update

BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah   Business: Cancer   Hired: Clint Carnell as president, CEO, and a director, formerly an executive in residence at Covidien plc ; he succeeds Harold Wolcott  ...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Financial News

BSD Medical financial update

BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah   Business: Cancer   Date announced: 2014-08-13   Note: BSD received notice from NASDAQ indicating that the company is not in compliance with the $1 minimum bid...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Financial News

BSD Medical completes direct public offering

BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah   Business: Cancer   Date completed: 4/9/13   Type: Direct public offering   Raised: $5 million   Shares: 4.1 million   Price: $1.23   Shares after offering:...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

BSD-2000 Hyperthermia System: Phase I/II started

BSD began the open-label, German Phase I/II HyRec trial to evaluate the BSD-2000 Hyperthermia System in combination with 5-fluorouracil (5-FU) and oxaliplatin chemotherapy and radiotherapy in about 59 patients. BSD-2000 has Humanitarian Device Exemption (HDE)...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Clinical News

BSD-2000 Hyperthermia System regulatory update

The National Comprehensive Cancer Network (NCCN) updated its clinical practice guidelines in oncology to include hyperthermia and chemotherapy as a recommended treatment for high-risk soft tissue sarcoma (STS) based on data from BSD's Phase III...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Financial News

BSD Medical completes direct public offering

BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah   Business: Cancer   Date completed: 11/15/10   Type: Direct public offering   Raised: $10.4 million   Shares: 1.8 million   Price: $5.97   Shares after offering:...
07:00 , May 10, 2010 |  BC Week In Review  |  Financial News

BSD Medical completes direct public offering

BSD Medical Corp. (NASDAQ: BSDM), Salt Lake City, Utah   Business: Cancer   Date completed: 5/3/10   Type: Direct public offering   Raised: $2.5 million   Shares: 1.6 million   Price: $1.52   Shares after...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

BSD-2000 Hyperthermia System: Phase III data

Data from an international Phase III trial in 341 patients with localized, high-risk STS showed that the BSD-2000 Hyperthermia System plus neoadjuvant chemotherapy with etoposide, ifosfamide and doxorubicin significantly reduced local tumor progression at 2...
08:00 , Feb 15, 2010 |  BC Week In Review  |  Clinical News

BSD-2000: Phase III started

BSD began an international Phase III trial to evaluate gemcitabine with or without the BSD-2000 Hyperthermia System in pancreatic cancer patients with surgical tumor resection. BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah   Product:...
07:00 , Apr 25, 2000 |  BC Extra  |  Clinical News

BSD Medical to start Phase I/II study

BSDM said it will start a U.S. Phase I/II trial combining hyperthermia with liposome-encapsulated doxorubicin to treat ovarian cancer....